PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study it to evaluate the efficacy of PTK787/ZK 222584, in inducing at
least a 50% reduction in paraprotein in patients with multiple myeloma whose paraprotein
levels are < 5 g/dL following high dose chemotherapy (HDCT) and autologous stem cell
transplantation (ASCT).